Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12266591 | 0.85 | CA2 (0.50) | CA2DPP4DPP8DPP9TLR2 | |
| SCHEMBL13566444 | 0.85 | CA2 (0.50) | CA2DPP4DPP8DPP9TLR2 | |
| SCHEMBL13566452 | 0.82 | GLP1R (0.43) | CA2MEN1KMT2AGLP1RCCKBR | |
| SCHEMBL21753974 | 0.80 | DPP4 (0.43) | CA2DPP4DPP8DPP9TLR2 | |
| SCHEMBL16093443 | 0.79 | GLP1R (0.53) | MEN1KMT2AGLP1RCCKBR | |
| SCHEMBL13010640 | 0.78 | GLP1R (0.42) | CA2MEN1KMT2AGLP1RSYK | |
| SCHEMBL12599304 | 0.78 | DPP7 (0.44) | CA2DPP4DPP8DPP9TLR2 | |
| SCHEMBL22923532 | 0.77 | CTSS (0.48) | GLP1RCCKBR | |
| SCHEMBL22923534 | 0.77 | CTSS (0.48) | GLP1RCCKBR | |
| SCHEMBL18291176 | 0.77 | CTSS (0.48) | GLP1RCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090148384-A1 | FUNCTIONALIZED, SOLID POLYMER NANOPARTICLES COMPRISING EPOTHILONES | BAYER SCHERING PHARMA AG (DE) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090148384-A1 | FUNCTIONALIZED, SOLID POLYMER NANOPARTICLES COMPRISING EPOTHILONES | EPOR, SELPLG, SELP | CA2 2179/4885DPP4 4620/4885DPP8 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.